Skip to content
HowShorted

Relay Therapeutics, Inc. short interest in 2022

In 2022, Relay Therapeutics, Inc.'s disclosed short interest ran from 12.81% of shares outstanding on 14 Jan 2022 to 13.97% on 30 Dec 2022, a change of +1.16 percentage points. The year's high was 18.78% on 30 Jun 2022 and its low 10.33% on 30 Nov 2022, averaging 13.93% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.57 days on 15 Mar 2022. Full history: Relay Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Relay Therapeutics, Inc. in 2022

2022 in figures

Start of year
12.81% (14 Jan 2022)
End of year
13.97% (30 Dec 2022)
Change
+1.16 pp
High
18.78% (30 Jun 2022)
Low
10.33% (30 Nov 2022)
Average
13.93%
Highest days to cover
27.57 (15 Mar 2022)
SEC filings marked
8

Every report in 2022

Relay Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202212.81%26.12
31 Jan 202213.77%20.15
15 Feb 202213.95%26.85
28 Feb 202214.24%21.8710-K filed, results (8-K)
15 Mar 202214.86%27.57
31 Mar 202213.53%21.24
14 Apr 202213.29%24.33
29 Apr 202213.48%26.20
13 May 202215.04%12.6410-Q filed, results (8-K)
31 May 202216.49%25.23
15 Jun 202216.89%20.35
30 Jun 202218.78%10.79
15 Jul 202217.50%21.80
29 Jul 202217.23%23.62
15 Aug 202216.91%20.5110-Q filed, results (8-K)
31 Aug 202214.35%15.53
15 Sep 202210.75%4.80
30 Sep 202211.19%10.33
14 Oct 202211.99%12.37
31 Oct 202211.13%13.03
15 Nov 202210.79%14.3110-Q filed, results (8-K)
30 Nov 202210.33%17.13
15 Dec 202211.11%12.03
30 Dec 202213.97%9.27

See also: Relay Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.